New drug candidate SCB0020160 enters first human safety tests
NCT ID NCT07682337
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 1 trial tests a new investigational drug, SCB0020160, for the first time in humans. Healthy adult men aged 18 to 65 receive either the drug or a placebo to evaluate safety, tolerability, and how the drug moves through the body. The study also looks at whether food affects drug absorption. There is no direct health benefit for participants, but results will help determine safe doses for future research in conditions like solid tumors, obesity, and idiopathic pulmonary fibrosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SCB0020160
What this could lead to
If safe and well-tolerated, this could pave the way for future studies of SCB0020160 in conditions like solid tumors, obesity, or idiopathic pulmonary fibrosis.
What could go wrong
This is an early, first-in-human trial with only 74 healthy men. It is designed to check safety, not to treat disease. Many early-stage drugs fail to show benefit or have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Periodontal Disease in Obesity Study | NCT04851470
- TAP Block Timing for Sleeve Gastrectomy Pain (NCT04787367)
- Fiber supplement gut health study in obese child NCT03968003
- PF-ILD Imaging Biomarker Study | NCT05492994
- Personalized Cancer Vaccine ABO2109 Trial NCT07680582
- IBR854 Cell Therapy for Solid Tumors - NCT06001684
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CMAX Clinical Research Pty Ltd Ground Floor, 21-24 North Terrace
Adelaide, South Australia, 5000, Australia